跳至主要内容
临床试验/2023-504360-42-00
2023-504360-42-00招募中4 期

Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients

Amsterdam UMC24 个研究点 分布在 2 个国家目标入组 3,090 人开始时间: 2023年4月3日最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
3,090
试验地点
24
主要终点
Major or minor bleeding defined as Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding at 12 months

研究概览

简要总结

This study will assess whether omitting aspirin reduces the rate of major or minor bleeding while remaining non-inferior to the current standard of care with regards to ischemic events in patients with non-ST segment elevation acute coronary syndrome.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Clinical diagnosis of NSTE-ACS (i.e. NSTEMI or unstable angina)
  • Successful PCI (according to the treating physician)

排除标准

  • Known allergy or contraindication for aspirin or all commercially available P2Y12-inhibitors (i.e. ticagrelor, prasugrel and clopidogrel)
  • Concurrent use of oral anticoagulants (e.g. because of atrial fibrillation)
  • Ongoing indication for DAPT at admission (e.g. due to recent PCI or ACS)
  • Planned surgical intervention within 12 months of PCI
  • Pregnant or breastfeeding women at time of enrolment
  • Participation in another trial with an investigational drug or device

结局指标

主要结局

Major or minor bleeding defined as Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding at 12 months

Major or minor bleeding defined as Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding at 12 months

Composite of all-cause mortality, myocardial infarction, and stroke at 12 months

Composite of all-cause mortality, myocardial infarction, and stroke at 12 months

次要结局

未报告次要终点

研究者

发起方
Amsterdam UMC
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

I.T. Küçük

Scientific

Amsterdam UMC

研究点 (24)

Loading locations...

相似试验